These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 8180297)

  • 1. Safety of proton pump inhibitors--an overview.
    Arnold R
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():65-70. PubMed ID: 8180297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton-pump inhibitors: three of a kind?
    Bateman DN
    Lancet; 1997 Jun; 349(9066):1637-8. PubMed ID: 9186377
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
    Brunner G; Harke U
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():59-64. PubMed ID: 8180296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
    Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
    Leonhardt U; Ritzel U; Ramadori G
    Internist (Berl); 1996 Sep; 37(9):944-9; discussion 949. PubMed ID: 8964694
    [No Abstract]   [Full Text] [Related]  

  • 9. The interaction of proton pump inhibitors with cytochromes P450.
    Tucker GT
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():33-8. PubMed ID: 8180292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.
    Brunner G; Athmann C; Boldt JH
    Dig Dis Sci; 2001 May; 46(5):993-6. PubMed ID: 11341670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
    Labenz J; Petersen KU; Rösch W; Koelz HR
    Aliment Pharmacol Ther; 2003 Apr; 17(8):1015-9. PubMed ID: 12694083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
    Martin RM; Dunn NR; Freemantle S; Shakir S
    Br J Clin Pharmacol; 2000 Oct; 50(4):366-72. PubMed ID: 11012560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug interactions with proton pump inhibitors.
    Unge P; Andersson T
    Drug Saf; 1997 Mar; 16(3):171-9. PubMed ID: 9098655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
    Bardhan KD; Cherian P; Bishop AE; Polak JM; Romanska H; Perry MJ; Rowland A; Thompson M; Morris P; Schneider A; Fischer R; Ng W; Lühmann R; McCaldin B
    Am J Gastroenterol; 2001 Jun; 96(6):1767-76. PubMed ID: 11419827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole.
    Huber R; Kohl B; Sachs G; Senn-Bilfinger J; Simon WA; Sturm E
    Aliment Pharmacol Ther; 1995 Aug; 9(4):363-78. PubMed ID: 8527612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent anaphylaxis associated with pantoprazole.
    Gratacós L; Soy D; Lluís M; López B; Nicolás JM; Codina C; Nogué S; Ribas J
    Am J Health Syst Pharm; 2005 Jul; 62(13):1388-9. PubMed ID: 15972383
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A; Mignon M; Samoyeau R
    Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of proton pump inhibitors.
    Der G
    Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent anaphylaxis linked to pantoprazole.
    Kollmeier AP; Eddleston J; Zuraw BL; Christiansen SC
    J Allergy Clin Immunol; 2004 Oct; 114(4):975-7. PubMed ID: 15480345
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.